May 31, 2024Open Access

Once-daily upadacitinib versus placebo in adults with extensive non-segmental vitiligo: a phase 2, multicentre, randomised, double-blind, placebo-controlled, dose-ranging study

Key Points

Key points are not available for this paper at this time.

Abstract

Janus kinase (JAK) inhibition is a promising approach for treating vitiligo. We aimed to assess the efficacy and safety of upadacitinib, an oral selective JAK inhibitor, in adults with non-segmental vitiligo.

Read Full Paperexternally

问 AI

Bookmark

View Full Paper

Cite This Study

Passeron et al. (Fri,) studied this question.

synapsesocial.com/papers/68e6761db6db6435875fffc3 https://doi.org/https://doi.org/10.1016/j.eclinm.2024.102655

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)2018 · 377 citations
2Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA2022 · 127 citations
3Autoimmune Destruction of Skin Melanocytes by Perilesional T Cells from Vitiligo Patients2009 · 527 citations
4Targeting Innate Immunity to Combat Cutaneous Stress: The Vitiligo Perspective2021 · 42 citations
5Economic Burden among Patients with Vitiligo in the United States: A Retrospective Database Claims Study2023 · 17 citations

问 AI

Bookmark

View Full Paper